LXEO vs. MRVI, RLAY, VECT, KROS, ARVN, MAZE, TYRA, VERV, OPT, and CGEM
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), VectivBio (VECT), Keros Therapeutics (KROS), Arvinas (ARVN), Maze Therapeutics (MAZE), Tyra Biosciences (TYRA), Verve Therapeutics (VERV), Opthea (OPT), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.
Lexeo Therapeutics vs.
Lexeo Therapeutics (NASDAQ:LXEO) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
Maravai LifeSciences received 35 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 59.81% of users gave Maravai LifeSciences an outperform vote.
Lexeo Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 314.80%. Maravai LifeSciences has a consensus target price of $6.64, indicating a potential upside of 190.54%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Maravai LifeSciences.
Lexeo Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Lexeo Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexeo Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat Lexeo Therapeutics' return on equity.
In the previous week, Maravai LifeSciences had 6 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 7 mentions for Maravai LifeSciences and 1 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.67 beat Maravai LifeSciences' score of 0.51 indicating that Lexeo Therapeutics is being referred to more favorably in the media.
Summary
Lexeo Therapeutics beats Maravai LifeSciences on 12 of the 19 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LXEO) was last updated on 6/10/2025 by MarketBeat.com Staff
